McKenzie R, Darsley M, Thomas N, Randall R, Carpenter C, Forbes E, Finucane M, Sack RB, Hall E, Bourgeois AL. A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC. Vaccine. 2008 (In press). Frech SA, Dupont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF, et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet. 2008; 371(9629):2019-25. McKenzie R, Venkatesan MM, Wolf MK, Islam D, Grahek S, Jones AM, Bloom A, Taylor DN, Hale TL, Bourgeois AL. Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate. Vaccine. 2008; 26(26):3291-6.
McKenzie R, Clemens JD. Natural Immunity with Exposure. In Travelers’ Diarrhea, 2nd edition. Ericson CD, Dupont HL, Steffen R (eds.), BC Decker Inc., Hamilton, Ontario, Canada. (In press). Taylor DN, Bourgeois AL, Erisson CD, Steffen R, Jiang ZD, Haake R, Dupont HL, and the Rifaximin study group. A randomized, double-blind, multicenter study of Rifaximin compared to placebo and with ciprofloxacin in the treatment of Traveler’s diarrhea. Amer Trop Med Hyg. 2006; 74:1060-1066. Kirkpatrick BD, McKenzie R, O’Neill JP, Larsson CJ, Bourgeois AL, Shimko J, Bentley M, Makin J, Chatfield S, Hindle Z, Fidler C, Robinson BE, Ventrone CH, Bansal N, Carpenter CM, Kutzko D, Hamlet S, LaPointe C,Taylor DN. 2005. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine. 2006; 24:116-123. Sack DA, Shimko J, Torres O, Bourgeois AL, Francia DS, Gustafsson B, Karnell A, Nyquist I, Svennerholm AM. Randomized, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. coli diarrhea for travellers to Guatemala and Mexico. Vaccine. 2007; 25(22):4392-400. Glenn GM, Villar CP, Flyer DC, Bourgeois AL, McKenzie R, Lavker RM , Frech SA. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: Use of skin pretreatment to disrupt the stratum corneum. Infect Immun. 2007; 75:2163-2170. McKenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K, Glenn G. Trancutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): Protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine. 2007; 25:3684-3691. Carpenter CM, Hall ER, Randall R, McKenzie R, Cassels F, Diaz N, Thomas N, Bedford P, Darsley, Gewert MC, Howard RB, Sack DA, Chang HS, Gomes G, Bourgeois, AL. Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers. Vaccine. 2006; 24:3709-3718. McKenzie R, Bourgeois AL, Engstrom F, Hall E, Chang HS, Gomes GJ, Kyle JL, Cassels F, Turner AK, Randall R, Darsley M, Lee C, Bedford P, Shimko J, Sack DA. Comparative safety and immunogencity of two attenuated enterotoxigenic Escherichia coli (ETEC) vaccine strains in healthy adults. Infect Immun. 2006; 74:994-1000. McKenzie R, Walker RI, Nabors GS, Carpenter CM, Gomes G, Forbes E, Tian JH, Yang HH, Pace JL, Jackson WJ, Bourgeois AL. Safety and immunogencity of an oral, inactivated, whole cell vaccine for Shigella sonnei: Preclinical studies and a phase I trial. Vaccine. 2006; 24:3735-3745. Taylor DN, McKenzie R, Durbin A, Carpenter C, Atzinger C, Haake R, Bourgeois AL. Rifaximin, a nonabsorbed oral antibiotic, prevents Shigellosis after experimental challenge. Clin Infect Dis. 2006; 42:1283-1288. Lee LH, Burg E, Baqar S, Bourgeois AL, Burr DH, Ewing CP, Trust TJ, Guerry P. Evaluation of a truncated recombinant flagellin subunit vaccine against Campylobacter jejuni. Infect Immun. 1999; 67:5799-5805.
|
